Vir Biotechnology Inc (VIR)

Net profit margin

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020
Net income (ttm) US$ in thousands -615,117 -600,747 -262,022 -143,740 515,837 1,142,694 1,077,810 1,216,116 528,584 -102,319 -297,356 -390,336 -298,665 -256,787 -220,492
Revenue (ttm) US$ in thousands 86,180 118,803 490,721 444,237 1,613,740 2,377,077 2,106,136 2,325,891 1,095,407 284,394 182,706 72,626 76,368 75,614 75,089
Net profit margin -713.76% -505.67% -53.40% -32.36% 31.97% 48.07% 51.17% 52.29% 48.25% -35.98% -162.75% -537.46% -391.09% -339.60% -293.64%

December 31, 2023 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $-615,117K ÷ $86,180K
= -713.76%

Vir Biotechnology Inc's net profit margin has been experiencing significant fluctuations over the past eight quarters. In Q4 2023, the net profit margin was -713.76%, indicating a substantial loss exceeding the total revenue generated. The trend improved in Q3 2023, but remained negative at -438.56%. The company's performance further improved in Q2 2023 with a lower negative net profit margin of -51.93%, which suggests that Vir Biotechnology incurred losses but at a reduced rate compared to previous quarters.

The negative net profit margins persisted into Q1 2023 with a figure of -32.19%, demonstrating continued operating losses for the company. However, the trend in the previous year was notably different, with positive net profit margins ranging from 31.92% in Q4 2022 to over 50% in Q3 and Q2 of 2022. These positive margins indicate that Vir Biotechnology was profitable in those quarters.

Overall, the fluctuating net profit margins suggest that Vir Biotechnology has been facing challenges in generating net profits, with recent quarters showing significant losses. It is important for the company to closely monitor its expenses and revenue generation capabilities to improve profitability and sustainable growth in the future.


Peer comparison

Dec 31, 2023